Fed. Circ. OKs Inequitable Conduct Ruling Against Regeneron
The Federal Circuit said Thursday a Regeneron Pharmaceuticals Inc. patent for a genetically modified mouse was unenforceable because of the biotechnology company's inequitable conduct at the patent office, upholding a lower...To view the full article, register now.
Already a subscriber? Click here to view full article